CFTR and cystic fibrosis: Alternatively, the cardiovascular effects of the CFTR-F508del mutation could contribute to morbidity and mortality if a hypotensive phenotype correlates with altered tissue perfusion or elicits a neurohumoral response that could exacerbate the secondary pulmonary hypertension seen in cystic fibrosis patients with chronic lung disease.